NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Syros Pharmaceuticals Inc (NASDAQ:SYRS) announced its earnings results on Tuesday, November, 12th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.01. The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. View Syros Pharmaceuticals' Earnings History.

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals.

7 Wall Street analysts have issued 1-year price objectives for Syros Pharmaceuticals' stock. Their forecasts range from $9.00 to $18.00. On average, they expect Syros Pharmaceuticals' share price to reach $13.83 in the next year. This suggests a possible upside of 91.1% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.

Media stories about SYRS stock have trended negative on Saturday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Syros Pharmaceuticals earned a news sentiment score of -2.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Syros Pharmaceuticals.

Syros Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,340,000 shares, an increase of 30.0% from the December 15th total of 1,800,000 shares. Based on an average daily volume of 470,100 shares, the short-interest ratio is currently 5.0 days. Currently, 7.6% of the shares of the company are short sold. View Syros Pharmaceuticals' Current Options Chain.

Some companies that are related to Syros Pharmaceuticals include Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS), Myovant Sciences (MYOV), Athenex (ATNX), ZEALAND PHARMA/S (ZEAL), Rocket Pharmaceuticals (RCKT), Karyopharm Therapeutics (KPTI), Enanta Pharmaceuticals (ENTA), Opko Health (OPK) and Portola Pharmaceuticals (PTLA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Avid Bioservices (CDMO), Global Blood Therapeutics (GBT), Galmed Pharmaceuticals (GLMD) and ImmunoGen (IMGN).

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYRS stock can currently be purchased for approximately $7.24.

Syros Pharmaceuticals has a market capitalization of $307.27 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.

The official website for Syros Pharmaceuticals is http://www.syros.com/.

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]